Wang Zuoyan, Ren Lihui, Liu Na, Lei Licheng, Ye Huiming, Peng Jianjun
Department of Cardiology, Beijing Shijitan Hospital, Capital Medical University..
Kardiol Pol. 2016;74(10):1160-1166. doi: 10.5603/KP.a2016.0065. Epub 2016 May 10.
The no-reflow phenomenon during primary percutaneous coronary intervention (pPCI) in patients with ST-elevation myocardial infarction (STEMI) can lead to poor outcomes. It has been shown that the monocytes may be involved in the pathogenesis of coronary artery disease and associated with high risk of myocardial infarction.
To assess the relation between admission monocyte count and angiographic no-reflow after pPCI.
A total of 236 patients with acute STEMI, who underwent pPCI, were enrolled. The patients were divided into two groups (no-reflow and normal reflow) based on post-pPCI Thrombolysis in Myocardial Infarction (TIMI) flow grade. No reflow was defined as TIMI flow grades ≤ 2, and normal reflow was defined as TIMI 3 flow grade. The monocyte count and other laboratory parameters were measured on admission before pPCI.
There were 43 (18.2%) patients in the no-reflow group and 193 (81.8%) patients in the normal-reflow group. Patients with no-reflow had significantly higher admission monocyte count (0.76 ± 0.48 × 109/L vs. 0.55 ± 0.29 × 109/L, p = 0.004). Also, white blood cell and neutrophil counts were significantly higher while haemoglobin was significantly lower in the no-reflow group. In multivariate analysis, monocyte count remained an independent predictor of angiographic no-reflow phenomenon (odds ratio [OR] 2.665, 95% confidence interwal [CI] 1.102-6.445, p = 0.030) together with low haemoglobin concentration (OR 0.978, 95% CI 0.961-0.995, p = 0.013).
Monocyte count on admission and low haemoglobin concentration were independent clinical predictors of no-reflow following pPCI in patients with STEMI. Our findings suggest that admission monocyte count may be available for early risk stratification of no-reflow after pPCI and might allow the improvement of strategies to prevent this phenomenon.
ST段抬高型心肌梗死(STEMI)患者在直接经皮冠状动脉介入治疗(pPCI)期间出现的无复流现象可导致不良预后。研究表明,单核细胞可能参与冠状动脉疾病的发病机制,并与心肌梗死的高风险相关。
评估入院时单核细胞计数与pPCI术后血管造影无复流之间的关系。
共纳入236例行pPCI的急性STEMI患者。根据pPCI术后心肌梗死溶栓治疗(TIMI)血流分级将患者分为两组(无复流组和正常复流组)。无复流定义为TIMI血流分级≤2级,正常复流定义为TIMI 3级血流。在pPCI术前入院时测量单核细胞计数和其他实验室参数。
无复流组有43例(18.2%)患者,正常复流组有193例(81.8%)患者。无复流患者入院时单核细胞计数显著更高(0.76±0.48×10⁹/L对0.55±0.29×10⁹/L,p = 0.004)。此外,无复流组白细胞和中性粒细胞计数显著更高,而血红蛋白显著更低。在多变量分析中,单核细胞计数与低血红蛋白浓度一起仍是血管造影无复流现象的独立预测因素(比值比[OR] 2.665,95%置信区间[CI] 1.102 - 6.445,p = 0.030)以及低血红蛋白浓度(OR 0.978,95% CI 0.961 - 0.995,p = 0.013)。
入院时单核细胞计数和低血红蛋白浓度是STEMI患者pPCI术后无复流的独立临床预测因素。我们的研究结果表明,入院时单核细胞计数可用于pPCI术后无复流的早期风险分层,并可能有助于改进预防这一现象的策略。